Point72's new 5.2% passive stake signals conviction in Immunocore's pipeline, particularly the Phase 3 TEBE-AM trial with topline OS data expected Q2 2027. Monitor for any future 13D conversion or additional stake increases, though the filing certifies passive intent.
Drug in focus
IMCR drug pipeline →KIMMTRAK
▲ Bullish Named in this SC 13G- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized (since January 2022). Label expansion into cutaneous melanoma depends on Phase 3 TEBE-AM data expected by end of 2026; if positive, an sBLA submission would follow, with potential approval in 2027-2028.
- Next catalyst
- None dated
What to watchThe key near-term catalyst is the Phase 3 TEBE-AM topline readout for KIMMTRAK in cutaneous melanoma, expected by end of 2026 (~4 months away). A positive result could double the addressable market; a negative readout would be a major setback. With ~16.4% of shares short and ~18.8 days to cover, a positive readout could trigger significant short-covering upside. Watch for enrollment completion announcements and any data updates at medical meetings in H2 2026.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $32.38entry
- T+1 · 6d ago −2.25%α −3.57% · $31.65
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Point72 Asset Management, L.P. (Steven Cohen's firm) filed a new Schedule 13G disclosing a 5.2% passive stake in Immunocore Holdings plc, representing 2,720,043 ordinary shares (including 501,604 shares issuable upon conversion of convertible notes) as of November 6, 2026. This is a new 5%+ disclosure from a prominent hedge fund, filed three days after Immunocore's Q3 earnings report showing flat KIMMTRAK revenue and a widened net loss.
Key Financial Metrics
Key Facts
- Point72 Asset Management disclosed a 5.2% passive stake in Immunocore Holdings plc as of November 6, 2026
- Stake consists of 2,720,043 ordinary shares, including 501,604 shares issuable upon conversion of convertible notes
- Filing is a new Schedule 13G (not an amendment), indicating Point72 crossed the 5% threshold
- Point72 certifies passive intent under Rule 13d-1(c), with no activist purpose
- Filing comes 3 days after Immunocore's Q3 2026 earnings (Nov 6), which showed KIMMTRAK revenue of $102.2M (down 1.4% YoY) and a net loss of $14.2M
Financial Impact
5.2% stake valued at approximately $78M based on $1.5B market cap
Risk Factors
- Point72 could convert to an activist 13D filing if it seeks changes, though no such intent is stated
- The stake includes 501,604 shares issuable upon convertible note conversion, adding potential dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000919574-26-007502 |
| Document: 0000919574-26-007502-index-headers.html | 0000919574-26-007502 |
| Document: 0000919574-26-007502-index.html | 0000919574-26-007502 |
| Document: 0000919574-26-007502.txt | 0000919574-26-007502 |
Track record
14 reports on IMCR
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +28.39% at T+60 after the May 31, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago SC 13G Neutral 4/10 Viewing Entry $32.38 Now $28.88 −10.81% settles Feb 8
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
- Sep 14, 20269w ago 8-K Bullish 6/10 Entry $32.46 Now $28.88 −11.03% settles Dec 8
- Aug 6, 202614w ago 8-K Mixed 5/10 Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
- May 31, 202624w ago Press Release Bullish 6/10 Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers